|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||
REVIEWS AND ORIGINAL ARTICLES |
From the Division ofNephrology, Department of Medicine, University of Missouri, MA436 Health Sciences Center, Columbia, Mo 652] 2, USA.
The authors evaluated risk factors for hyperaluminemia and aluminum
toxicity in 51 CAPD patients, who received aluminum-containing phosphate
binders. Serum aluminum correlated with total intake of elemental aluminum
after starting CAPD (p = 0.001), with aluminum intake in the previous six
months (p = 0.001), with duration of CAPD (p = 0.003), and with serum
phosphate (p = 0.05). Eight patients had elevated serum aluminum, but only one
had clincial evidence of aluminum toxicity (he had been on hemodialysis with
untreated water until he was changed to CAPD 30 months before the study).
Although the incidence of clinical aluminum toxicity appears to be low, we
conclude that the aluminum intake from aluminum-containing phosphate binders
is a major factor in the evolution of hyperaluminemia and, potentially,
aluminum toxicity in CAPD patients. We believe that alternative effective,
phosphate binders are much needed.
KEY WORDS: Risk factors; Serum aluminum; Aluminum toxicity; Aluminum containing phosphate binders.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |